Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 771-781

  Forloni, Gianluigi ^a   Artuso, Vladimiro ^b   La Vitola, Pietro ^a   Balducci, Claudia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CA FONCELLO HOSPITAL   (Italy)

Author keywords

Aggregation; Alpha synuclein; Beta amyloid; Neurodegeneration; Spreading

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; SYNTHETIC PEPTIDE; TAU PROTEIN;

ALZHEIMER DISEASE; BETA SHEET; BIOLOGICAL ACTIVITY; CHANNEL GATING; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; INTRACELLULAR MEMBRANE; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM; PATHOLOGY; PROTEOSTASIS DEFICIENCY;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; PARKINSON DISEASE; PROTEOSTASIS DEFICIENCIES;

EID: 84963805193     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26624     Document Type: Review

References (157)

1. Forloni G, Terreni L, Bertani I, et al. Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging 2002;23:957-976.
2. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006296.
3. Buratti E. Functional significance of TDP-43 mutations in disease. Adv Genet 2015;91:1-53.
4. Lippa CF, Saunders AM, Smith TW, et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 1996;46:406-412.
5. Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A prospective study of familial versus sporadic Parkinson's disease. Neurodegener Dis 2007;4:424-427.
6. Armstrong RA. Spatial patterns of β-amyloid (Aβ) deposits in familial and sporadic Alzheimer's disease. Folia Neuropathol 2011;49:153-161.
7. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
8. Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000 283:1571-1577.
9. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003;4:49-60.
10. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol 1991;207:367-368.
11. Forloni G, Lucca E, Angeretti N, Della Torre P, Salmona M. Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J Neurochem 1997;69:2048-2054.
12. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-6453.
13. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997;4:119-125.
14. Walsh DM, Hartley DM, Kusumoto Y, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999;274:25945-25952.
15. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
16. Chen QS, Kagan BL, Hirakura Y, Xie CW. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 2000;60:65-72.
17. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C. The "Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001;4:887-893.
18. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003;100:10417-10422.
19. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008;63:377-387.
20. Upadhaya AR, Lungrin I, Yamaguchi H, Fändrich M, Thal DR. High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain. J Cell Mol Med 2012;16:287-295.
21. Sokolow S, Henkins KM, Bilousova T, et al. AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging 2012;33:1545-1555.
22. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 1999;96:3228-3233.
23. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 1999;29:177-185.
24. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 2003;17:388-396.
25. Balducci C, Tonini R, Zianni E, et al. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AßPP23 transgenic mice. J Alzheimers Dis 2010;21:1367-1381.
26. De Kosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990;27:457-464.
27. Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004;24:10191-10200.
28. Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging 2011;32:1784-1794.
29. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-1058.
30. Come JH, Fraser PE, Lansbury PT Jr. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A 1993;90:5959-5963.
31. Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007;27:9220-9232.
32. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010;49:10039-10041.
33. Lee S, Kim HJ. Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp Neurobiol 2015;24:1-7.
34. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010;33:317-325.
35. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
36. Klingelhoefer L, Reichmann H Pathogenesis of Parkinson disease-the gut-brain axis and environmental factors. Nat Rev Neurol 2015, 11:625-636.
37. Aguzzi A, Lakkaraju AK. Cell Biology of prions and prionoids: a status report. Trends Cell Biol 2016;26:40-51.
38. Chang YJ, Chen YR. The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway. FEBS J 2014;281:2674-2687.
39. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B. Globular amyloid beta-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 2005;95:834-847.
40. 1-42 from the corresponding depsipeptides. Anal Biochem 2011;411:297-299.
41. Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A-Beta(N3-(Pe)), in senile plaques. Neuron 1995;14:457-466.
42. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature 2012;485:651-655.
43. Frost JL, Le KX, Cynis H, et al. Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol 2013, 183:369-381.
44. Mandler M, Walker L, Santic R, et al. Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease. Acta Neuropathol 2014;128: 67-79.
45. Gillman AL, Jang H, Lee J, et al. Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) pores. J Phys Chem B 2014;118:7335-7344.
46. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003;42:12749-12760.
47. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-357.
48. Lesné SE, Sherman MA, Grant M, et al. Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain 2013;136:1383-1398.
49. Liu P, Reed MN, Kotilinek LA, et al. quaternary structure defines a large class of amyloid-β oligomers neutralized by sequestration. Cell Rep 2015;11:1760-1771.
50. Roberts HL, Brown DR. Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules 2015;5:282-305.
51. Lee J, Culyba EK, Powers ET, Kelly JW. Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 2011;7:602-609.
52. Fu Z, Aucoin D, Davis J, Van Nostrand WE, Smith SO. mechanism of nucleated conformational conversion of Aβ42. Biochemistry 2015;54:4197-4120.
53. Ladiwala AR, Litt J, Kane RS, Aucoin DS, Smith SO, Ranjan S. Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. J Biol Chem 2012;287:24765-24773.
54. Zampagni M, Cascella R, Casamenti F, Grossi C, Evangelisti E, Wright D. A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. J Cell Mol Med 2011;15:2106-2116.
55. Tatini F, Pugliese AM, Traini C, et al. Amyloid-β oligomer synaptotoxicity is mimicked by oligomers of the model protein HypF-N. Neurobiol Aging 2013;34:2100-2109.
56. Tsigelny IF, Sharikov Y, Kouznetsova VL, et al. Structural diversity of Alzheimer's disease amyloid-β dimers and their role in oligomerization and fibril formation. J Alzheimers Dis 2014;39:583-600.
57. Forloni G, Chiesa R, Smiroldo S, et al. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport 1993;4:523-526.
58. Malaplate-Armand C, Florent-Béchard S, Youssef I, et al. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 2006;23:178-189.
59. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012;15:349-357.
60. Chakravarthy B, Gaudet C, Ménard M, et al. Amyloid-beta peptides stimulate the expression of the p75(NTR) neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice. J Alzheimers Dis 2010;19:915-925.
61. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-4133.
62. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000;275:5626-5632.
63. Liu Q, Kawai H, Berg DK. Beta-amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A 2001;98:4734-4739.
64. Liu Q, Xie X, Emadi S, Sierks MR, Wu J. A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity. Neuropharmacology 2015;97:457-463.
65. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005;8:1051-1058.
66. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011;31:6627-6638.
67. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener 2014;14;9:48.
68. Yaar M, Zhai S, Pilch PF, et al. Gilchrest BA Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest 1997;100:2333-2340.
69. Ito S, Ménard M, Atkinson T, et al. Involvement of insulin-like growth factor 1 receptor signaling in the amyloid-β peptide oligomers-induced p75 neurotrophin receptor protein expression in mouse hippocampus. J Alzheimers Dis 2012;31:493-506.
70. Wang QW, Rowan MJ, Anwyl R. Inhibition of LTP by beta amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. Neurobiol Aging 2009;30:1608-1613.
71. Li S, Jin M, Zhang D, et al. Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ oligomers. Neuron 2013;77:929-941.
72. Cissé M, Halabisky B, Harris J, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011;469:47-52.
73. Fu AK, Hung KW, Huang H, et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A 2014;111:9959-9964.
74. Kam TI, Song S, Gwon Y, et al. FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest 2013;123:2791-2802.
75. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009;106:1971-1976.
76. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J Clin Invest 2012;122:1339-1353.
77. Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009;29:9078-9089.
78. Viola KL, Klein WL. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 2015;129:183-206.
79. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009;457:1128-1132.
80. Nieznanski K, Surewicz K, Chen S, Nieznanska H, Surewicz WK. Interaction between prion protein and Aβ amyloid fibrils revisited. ACS Chem Neurosci 2014;5:340-345.
81. Ganzinger KA, Narayan P, Qamar SS, et al. Single-molecule imaging reveals that small amyloid-β1-42 oligomers interact with the cellular prion protein (PrP(C). Chembiochem 2014;15:2515-2521.
82. Balducci C, Beeg M, Stravalaci M, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A 2010;107:2295-2300.
83. Fluharty BR, Biasini E, Stravalaci M, et al. An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 2013;288:7857-7866.
84. Forloni G, Sclip A, Borsello T, Balducci C. The neurodegeneration in Alzheimer disease and the prion protein. Prion 2013;7:60-65.
85. Kim T, Vidal GS, Djurisic M, et al. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 2013;341:1399-1404.
86. Xia M, Cheng X, Yi R, Gao D, Xiong J. The binding receptors of aβ: an alternative therapeutic target for alzheimer's disease. Mol Neurobiol 2016;53:455-471.
87. Goedert M, Spillantini MG. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry 1998;3:462-465.
88. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008;115:399-407.
89. Ruffmann C, Calboli FC, Bravi I, et al. Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases [published online ahead of print November 3, 2015]. Neuropathol Appl Neurobiol. doi: 10.1111/nan.12294.
90. Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998;44:415-422.
91. Bancher C, Lassmann H, Budka H, et al. An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 1989;48:81-93.
92. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
93. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-475.
94. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003;4:727-738.
95. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318-1320.
96. Lashuel HA, Petre BM, Wall J, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322:1089-1102.
97. Chen SW, Drakulic S, Deas E, et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci U S A 2015;112:E1994-E2003.
98. Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014;137:1496-1513.
99. Cremades N, Cohen SI, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012;149:1048-1059.
100. Barrett PJ, Greenamyre TJ Post-translational modification of α-synuclein in Parkinson's disease [published online ahead of print June 14, 2015]. Brain Res.
101. Borghi R, Marchese R, Negro A, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000;287:65-67.
102. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna) 2006;113:1435-1439.
103. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-425.
104. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-503.
105. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506.
106. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006;313:1781-1784.
107. Mendez I, Viñuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008;14:507-509.
108. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012;209:975-986.
109. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-953.
110. Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun 2014;2:88.
111. Peelaerts W, Bousset L, Van der Perren A, et al. α-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015;522:340-344.
112. Sacino AN, Brooks M, Thomas MA, et al. Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A 2014;111:10732-10737.
113. Jones DR, Delenclos M, Baine AT, et al. transmission of soluble and insoluble α-synuclein to mice. J Neuropathol Exp Neurol 2015;74:1158-1169.
114. Dehay B, Vila M, Bezard E, Brundin P, Kordower JH. Alpha-synuclein propagation: new insights from animal models. Mov Disord 2016;31:161-168.
115. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci 2012;32:3301-3305.
116. Han H, Weinreb PH, Lansbury PT Jr. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol 1995;2:163-169.
117. Forloni G, Bertani I, Calella AM, Thaler F, Invernizzi R. Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 2000;47:632-640.
118. Albani D, Peverelli E, Rametta R, et al. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J 2004;18:1713-1715.
119. Batelli S, Invernizzi RW, Negro A, et al. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity. Neurodegener Dis 2015;15:13-23.
120. Zondler L, Miller-Fleming L, Repici M, et al. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. Cell Death Dis 2014;5:e1350.
121. Diógenes MJ, Dias RB, Rombo DM, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012;22:32-40.
122. Tozzi A, de Iure A, Bagetta V, et al. Alpha-synuclein produces early behavioral alterations via striatal cholinergic synaptic dysfunction by interacting with glun2d n-methyl-d-aspartate receptor subunit. Biol Psychiatry 2016;79:402-414.
123. Eschbach J, von Einem B, Müller K, et al. Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol 2015;77:15-32.
124. Ferreira DG, Batalha VL, Vicente Miranda H, et al. Adenosine a2a receptors modulate α-synuclein aggregation and toxicity [published online ahead of print November 2, 2015]. Cereb Cortex.
125. Ebrahim AS, Ko LW, Yen SH. Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein. Neurosci Lett 2010;473:120-125.
126. Eschbach J, von Einem B, Müller K, et al. Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol 2015;77:15-32.
127. Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol 2011;121:675-679.
128. Brück D, Wenning GK, Stefanova N, Fellner L. Glia and alpha-synuclein in neurodegeneration: a complex interaction. Neurobiol Dis 2016;85:262-274.
129. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 2011;69:337-342.
130. Klegeris A, Pelech S, Giasson BI, et al. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 2008;29:739-752.
131. Couch Y, Alvarez-Erviti L, Sibson NR, Wood MJ, Anthony DC. The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation 2011;8:166.
132. Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994;180:147-150.
133. Yan J, Fu Q, Cheng L, et al. Inflammatory response in Parkinson's disease. Mol Med Rep 2014;10:2223-2233.
134. Nie K, Zhang Y, Gan R, et al. Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population. Neurosci Lett 2013;541:111-115.
135. Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson's disease. Neuroscience 2015;302:89-102.
136. Allen Reish HE, Standaert DG. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 2015;5:1-19.
137. Balducci C, Forloni G. In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches. Curr Pharm Des 2014;20:2491-2505.
138. Lowndes GJ, Saling MM, Ames D, Chiu E, Gonzalez LM, Savage GR. Recall and recognition of verbal paired associates in early Alzheimer's disease. J Int Neuropsychol Soc 2008;14:591-600.
139. Figueiredo CP1, Clarke JR, Ledo JH, et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight Aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers J Neurosci 2013;33:9626-9634.
140. Fluharty BR, Biasini E, Stravalaci M, et al. An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 2013;288:7857-7866.
141. Balducci C, Paladini A, Micotti E, et al. The continuing failure of bexarotene in Alzheimer's disease mice. J Alzheimers Dis 2015;46:471-482.
142. Morris GP, Clark IA, Zinn R, Vissel B. Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol Learn Mem 2013;105:40-53.
143. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015;14:388-405.
144. Martin ZS, Neugebauer V, Dineley KT, et al. α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem 2012;120:440-452.
145. Diógenes MJ, Dias RB, Rombo DM, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012;32:11750-11762.
146. Surendranathan A, Rowe JB, O'Brien JT Neuroinflammation in Lewy body dementia. Parkinsonism Relat Disord 2015;21:1398-1406.
147. Zhou B, Wen M, Yu WF, Zhang CL, Jiao L. The diagnostic and differential diagnosis utility of cerebrospinal fluid α -synuclein levels in Parkinson's disease: a meta-analysis. Parkinsons Dis 2015;2015:567386.
148. Yang T, O'Malley TT, Kanmert D, et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimers Res Ther 2015;7:14.
149. Manzoni C, Colombo L, Bigini P, et al. The molecular assembly of amyloid aβ controls its neurotoxicity and binding to cellular proteins. PLoS ONE 2011;6:e24909.
150. Valera E, Spencer B, Masliah E. Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 2016 13:179-189.
151. Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. J Neurochem 2013;126:473-482.
152. Bodani RU, Sengupta U, Castillo-Carranza DL, et al. antibody against small aggregated peptide specifically recognizes toxic aβ-42 oligomers in Alzheimer's disease. ACS Chem Neurosci 2015;6:1981-1989.
153. Meli G, Lecci A, Manca A, et al. Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nat Commun 2014;5:3867.
154. Lindström V, Fagerqvist T, Nordström E, et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol Dis 2014;69:134-143.
155. Forloni G, Tettamanti M, Lucca U, et al. Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Prion 2015;9:75-79.
156. McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord 2016;31:152-160.
157. Caldinelli L, Albani D, Pollegioni L. One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli. BMC Biotechnol 2013;13:32.